Mesoblast to Meet With FDA Subsequent Month to Talk about Rexlemestrocel-L and Opioid Cessation

Mesoblast Restricted (Nasdaq:MESO; ASX:MSB), international chief in allogeneic mobile medicines for inflammatory ailments, in the present day introduced that the U.S. Meals & Drug Administration (FDA) has scheduled a gathering in early December to debate Mesoblast’s knowledge on opioid discount and cessation from its first Section 3 examine (MSB-DR003) of rexlemestrocel-L in sufferers with power low again ache (CLBP).

In Mesoblast’s first randomized managed Section 3 trial of 404 sufferers, 168 of whom have been taking opioids at baseline, greater than 3-fold greater numbers of sufferers handled with a single intra-discal injection of rexlemestrocel-L + HA have been capable of stop use of all opioids by 36 months in contrast with saline-treated controls (p=0.008).

In mild of the devastating opioid disaster that continues to rage within the US, in September 2025 FDA supplied new Steering to Business on Growth of Non-Opioid Brokers for Remedy of Persistent Ache. ¹ Since CLBP is the principal explanation for power prescription opioid use, there’s a vital want for a secure, efficient, and sturdy opioid-sparing therapy in sufferers with CLBP related to degenerative disc illness.

Mesoblast Chief Govt Silviu Itescu mentioned: “FDA has emphasised the significance of growing non opioid therapies for power ache, and we stay up for discussing plans for rexlemestrocel-L as an agent that will end in each amelioration of CLBP in addition to opioid discount or cessation.”

Rexlemestrocel-L has acquired Regenerative Drugs Superior Remedy (RMAT) designation for therapy of CLBP as a consequence of degenerative disc illness, a severe situation that could be a main contributory issue to the nation’s opioid disaster. Mesoblast is looking for FDA approval primarily based on discount in CLBP by means of 12 months and is actively recruiting a 300-patient confirmatory Section 3 trial throughout 40 websites within the US, with enrollment anticipated to be accomplished within the coming quarter.

About Rexlemestrocel-L for Persistent Low Again Ache related to Degenerative Disc Illness
The 300-patient randomized managed confirmatory Section 3 trial of Mesoblast’s second era allogeneic, STRO3-immunoselected, and industrially manufactured stromal cell product candidate rexlemestrocel-L together with hyaluronic acid (HA) as supply agent for injection into the lumbar disc is actively enrolling in sufferers with power low again ache (CLBP) as a consequence of inflammatory degenerative disc illness (DDD) of lower than 5 years period at a number of websites throughout the U.S.

FDA has beforehand agreed on the design of this 300-patient randomized, placebo-controlled confirmatory Section 3 trial, and the 12-month major endpoint of ache discount as an approvable indication. This endpoint was efficiently met in Mesoblast’s first Section 3 trial. Key secondary measures embody enchancment in high quality of life and performance.

A selected focus is on therapy of sufferers on opioids, since discogenic again ache accounts for about 50% of prescription opioid utilization within the US. Important ache discount and opioid cessation have been noticed in Mesoblast’s first Section 3 trial.

FDA has designated rexlemestrocel-L a Regenerative Drugs Superior Remedy (RMAT) for the therapy of power low again ache. RMAT designation gives all the advantages of Breakthrough and Quick Observe designations, together with rolling evaluation and eligibility for precedence evaluation on submitting of a Biologics License Utility (BLA).

About Persistent Low Again Ache
Again ache is the main explanation for incapacity in People underneath 45 years, ² with an annual prevalence within the basic US grownup inhabitants of 10-30%. ³ CLBP attributable to irritation and degenerative disc illness (DDD) is a severe situation with a prevalence of over 7 million folks within the US alone. ^4,5 CLBP as a consequence of DDD is a number one explanation for incapacity, and is related to impaired high quality of life, extreme limitations in skill to carry out actions of every day residing, diminished skill to work, and adverse impacts on psychological well being. CLBP accounts for about 50% of prescription opioid utilization within the US, ⁵ making the situation a major contributor to the opioid epidemic.

About Mesoblast
Mesoblast (the Firm) is a world chief in growing allogeneic (off-the-shelf) mobile medicines for the therapy of extreme and life-threatening inflammatory situations. The therapies from the Firm’s proprietary mesenchymal lineage cell remedy know-how platform reply to extreme irritation by releasing anti-inflammatory elements that counter and modulate a number of effector arms of the immune system, leading to vital discount of the damaging inflammatory course of.

Mesoblast’s Ryoncil ^® (remestemcel-L-rknd) for the therapy of steroid-refractory acute graft versus host illness (SR-aGvHD) in pediatric sufferers 2 months and older is the primary FDA-approved mesenchymal stromal cell (MSC) remedy. Please see the total Prescribing Info at www.ryoncil.com .

Mesoblast is dedicated to growing extra cell therapies for distinct indications primarily based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell know-how platforms. Ryoncil ^® is being developed for extra inflammatory ailments together with SR-aGvHD in adults and biologic-resistant inflammatory bowel illness. Rexlemestrocel-L is being developed for coronary heart failure and power low again ache. The Firm has established industrial partnerships in Japan, Europe and China.

About Mesoblast mental property: Mesoblast has a powerful and in depth international mental property portfolio, with over 1,000 granted patents or patent purposes protecting mesenchymal stromal cell compositions of matter, strategies of producing and indications. These granted patents and patent purposes present industrial safety extending by means of to no less than 2044 in all main markets.

About Mesoblast manufacturing: The Firm’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, mobile medicines. These cell therapies, with outlined pharmaceutical launch standards, are deliberate to be available to sufferers worldwide.

Mesoblast has areas in Australia, the US and Singapore and is listed on the Australian Securities Trade (MSB) and on the Nasdaq (MESO). For extra info, please see www.mesoblast.com , LinkedIn: Mesoblast Restricted and Twitter: @Mesoblast

References / Footnotes

1. United States Meals & Drug Administration. Growth of Non-Opioid Analgesics for Persistent Ache Steering for Business. Draft Steering. September 2025
2. American Academy of Ache Drugs – Get the Info on Ache. The American Academy of Ache Drugs. http://www.painmed.org/patientcenter/facts-on-pain/ Accessed on June 28, 2017.
3. Urits I, Burshtein A, Sharma M, et al. Low Again Ache, a Complete Overview: Pathophysiology, Analysis, and Remedy. Present Ache and Headache Reviews. 2019;23(3):1-10. doi:10.1007/s11916-019-0757-1.
4. Navigant: Business Evaluation for a Proprietary Cell-Primarily based Remedy for DDD within the U.S. and the EU3 – August 2014.
5. Choice Sources: Persistent Ache December 2015.

Ahead-Wanting Statements
This press launch consists of forward-looking statements that relate to future occasions or our future monetary efficiency and contain recognized and unknown dangers, uncertainties and different elements that will trigger our precise outcomes, ranges of exercise, efficiency or achievements to vary materially from any future outcomes, ranges of exercise, efficiency or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the secure harbor provisions of the Non-public Securities Litigation Reform Act of 1995 and different federal securities legal guidelines. Ahead-looking statements shouldn’t be learn as a assure of future efficiency or outcomes, and precise outcomes could differ from the outcomes anticipated in these forward-looking statements, and the variations could also be materials and antagonistic. Ahead-looking statements embody, however should not restricted to, statements about: the initiation, timing, progress and outcomes of Mesoblast’s preclinical and scientific research, and Mesoblast’s analysis and growth packages; Mesoblast’s skill to advance product candidates into, enroll and efficiently full, scientific research, together with multi-national scientific trials; Mesoblast’s skill to advance its manufacturing capabilities; the timing or probability of regulatory filings and approvals, manufacturing actions and product advertising actions, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and some other product candidates, if accepted; regulatory or public perceptions and market acceptance surrounding the usage of stem-cell primarily based therapies; the potential for Mesoblast’s product candidates, if any are accepted, to be withdrawn from the market as a consequence of affected person antagonistic occasions or deaths; the potential advantages of strategic collaboration agreements and Mesoblast’s skill to enter into and keep established strategic collaborations; Mesoblast’s skill to ascertain and keep mental property on its product candidates and Mesoblast’s skill to efficiently defend these in instances of alleged infringement; the scope of safety Mesoblast is ready to set up and keep for mental property rights protecting its product candidates and know-how; estimates of Mesoblast’s bills, future revenues, capital necessities and its wants for extra financing; Mesoblast’s monetary efficiency; developments regarding Mesoblast’s opponents and business; and the pricing and reimbursement of Mesoblast’s product candidates, if accepted. You need to learn this press launch along with our danger elements, in our most just lately filed stories with the SEC or on our web site. Uncertainties and dangers that will trigger Mesoblast’s precise outcomes, efficiency or achievements to be materially completely different from these which can be expressed or implied by such statements, and accordingly, you shouldn’t place undue reliance on these forward-looking statements. We don’t undertake any obligations to publicly replace or revise any forward-looking statements, whether or not because of new info, future developments or in any other case.

Launch approved by the Chief Govt.

For extra info, please contact: